Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daraxonrasib (RMC-6236) vs SOC in Previously Treated Metastatic PDAC
NCT06625320Phase 3Active, not recruiting
- Sponsor
- Revolution Medicines
- Start
- Oct 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 7
01
Overview
A Phase 3 trial of daraxonrasib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Revolution Medicines. Started Oct 2024; status: active, not recruiting.
02
Drugs
daraxonrasib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06625320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625320.